UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044697
Receipt number R000050710
Scientific Title Evaluation of the intestinal environment improving effect of fucoidan
Date of disclosure of the study information 2021/12/01
Last modified on 2021/06/26 08:38:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the intestinal environment improving effect of fucoidan

Acronym

Evaluation of the intestinal environment improving effect of fucoidan

Scientific Title

Evaluation of the intestinal environment improving effect of fucoidan

Scientific Title:Acronym

Evaluation of the intestinal environment improving effect of fucoidan

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Effect of fucoidan intake on the intestinal flora

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Intestinal flora

Key secondary outcomes

Organic acids (short chain fatty acids), low molecular weight metabolites


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

1) Ingestion period
Initially, subjects do not ingest fucoidan food for 14 days. The subject then continues to intake fucoidan food for 14 days.
2) Intake
To ingest 30 mL / day of fucoidan food for 14 days

A fucoidan food with a daily intake of 30 mL contains a dry weight of 810 mg of fucoidan.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Healthy adult man and woman
2) Persons who voluntarily agreed to participate in writing after understanding the purpose of the study through informed consent

Key exclusion criteria

none

Target sample size

6


Research contact person

Name of lead principal investigator

1st name Hiroko
Middle name
Last name Hoshi

Organization

Maebashi Institute of Technology

Division name

Department of Biotechnology

Zip code

371-0816

Address

460-1 kamisadori-machi, maebashi, Gunma 371-0816, Japan

TEL

027-265-7373

Email

hihoshi@maebashi-it.ac.jp


Public contact

Name of contact person

1st name Sunao
Middle name
Last name Abe

Organization

Marine Products Kimuraya Co., Ltd.,

Division name

R and D division

Zip code

684-0072

Address

3307 Watari-cho, Sakaiminato, Tottori 684-8790, Japan

TEL

0859-45-6555

Homepage URL


Email

abe@mozuku-1ban.jp


Sponsor or person

Institute

Department of Biotechnology, Maebashi Institute of Technology

Institute

Department

Personal name



Funding Source

Organization

R and D division, Marine Products Kimuraya Co., Ltd.,

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Human Function Experiment Ethics Review Committee of the Maebashi Institute of Technology

Address

460-1 kamisadori-machi, maebashi, Gunma 371-0816, Japan

Tel

027-265-0111

Email

ynomura@maebashi-it.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

6

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 08 Month 04 Day

Date of IRB

2020 Year 08 Month 04 Day

Anticipated trial start date

2020 Year 10 Month 01 Day

Last follow-up date

2021 Year 09 Month 01 Day

Date of closure to data entry

2021 Year 10 Month 01 Day

Date trial data considered complete

2021 Year 11 Month 01 Day

Date analysis concluded

2021 Year 12 Month 01 Day


Other

Other related information



Management information

Registered date

2021 Year 06 Month 29 Day

Last modified on

2021 Year 06 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050710


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name